Risk Evaluation and Mitigation Strategies (REMS) are special safety programs required by the U.S. Food and Drug Administration (FDA) for certain drugs and biologics with serious safety concerns. These programs are designed to ensure that a product’s benefits outweigh its risks. REMS may include strategies such as restricted distribution, prescriber certification, patient education, training, and ongoing monitoring and reporting. These requirements are customized for each product and can range from simple Medication Guides to complex systems involving multiple stakeholders. This article provides an overview of REMS inspections and audits, outlines key focus areas for FDA reviewers and inspectors, and offers practical strategies for compliance.
Although REMS are relatively rare—fewer than 100 approved REMS programs are active today—the burden of compliance for affected companies is significant. Manufacturers and application holders are required to implement these programs as approved, track their effectiveness, and submit periodic assessments to the FDA. Inadequate REMS implementation can lead to regulatory consequences, including warning letters, product seizures, and even market withdrawal. Consequently, the FDA has increased its oversight of REMS programs, including routine and for-cause audits and inspections.
Know more about our Regulatory Services in USA
To get the daily updates, follow us on:
Facebook — https://www.facebook.com/DDReg
LinkedIn — https://www.linkedin.com/company/ddregpharma/
Twitter — https://x.com/DDRegPharma
Instagram — https://www.instagram.com/ddregpharma/
You must be logged in to post a comment.